Long-term effects of inhaled budesonide on screening-detected lung nodules

摘要: ABSTRACT We evaluated the long-term outcomes of a randomized, double-blind, placebo-controlled phase IIb trial inhaled budesonide in 202 current and former smokers with persistent CT-detected lung nodules. Budesonide significantly decreased size non-solid nodules after 5 years. This is potential importance since some these may progress slowly to adenocarcinoma. Background A previously carried out randomized IIb, 1 year budesonide, which was nested cancer screening study, showed that partially solid detected by low-dose computed tomography (LDCT), not immediately suspicious for cancer, tended regress. Because be slow-growing adenocarcinoma precursors, we (after stopping 1-year intervention) annual LDCT. Patients methods analyzed evolution target non-target LDCT placebo arms up years randomization. The numbers characteristics cancers diagnosed during follow-up were also analyzed. Results mean maximum diameter reduced (from 5.03 mm at baseline 2.61 mm years) arm; there no significant change arm. lesions significantly, but only 0.69 mm. did change. Neither number new nor differed two arms. Conclusions Inhaled given However, further studies are required assess clinical implications. Clinical NCT01540552.